Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed Tests ...
Genomic sequencing has come a long way in a short time, and its potential to drive even faster innovations in precision medicine is enormous. To capitalize on that opportunity, however, health systems ...
Life sciences and diagnostics company Revvity has had a busy couple of years, playing a major role in the next-generation sequencing-based screening of newborns to better enable healthcare ...
The "Canada Next-Generation Sequencing (NGS) Market - A Canada and Regional Analysis: Focus on Application, Technology, ...
The landscape of next-generation sequencing (NGS) continues to be defined by astonishing technological progress. We continue ...
Patients with multiple CALMs w/wo skinfold freckling and no other typical NF1 associated features (Lisch nodules, bone abnormalities, neurofibromas, optic pathway gliomas). The DNA-based ...
Located on the Buffalo Niagara Medical Campus and the first next-generation sequencing service provider in the region, UB's Genomics and Bioinformatics Core Facility provides high-quality services ...
Healthcare Asia Magazine on MSN
Next-generation sequencing services market to reach $8.77b by 2030
The growing use of precision medicine and genomics drives the sector. The global next-generation sequencing services market is expected to reach $8.77b by 2030 at a compound annual growth rate (CAGR) ...
Patients with classic NF1 including the presence of cutaneous neurofibromas or Lisch nodules, as no genetic heterogeneity demonstrated so far associated with this phenotype. The NF1-only by NGS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback